Last reviewed · How we verify
Parlodel (BROMOCRIPTINE)
Parlodel (BROMOCRIPTINE) is a small molecule ergot derivative that targets the D(2) dopamine receptor. It was originally developed by US PHARMS HOLDINGS I and is now owned by Esjay Pharma. Parlodel is FDA-approved for various indications, including Acromegaly, Hyperprolactinemia, Parkinson's disease, Postencephalitic parkinsonism, and Type 2 Diabetes Mellitus Treatment Adjunct. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include its potential for side effects such as nausea and dizziness.
At a glance
| Generic name | BROMOCRIPTINE |
|---|---|
| Sponsor | Esjay Pharma |
| Drug class | Ergot Derivative |
| Target | D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Acromegaly
- Hyperprolactinemia
- Parkinson's disease
- Postencephalitic parkinsonism
- Type 2 Diabetes Mellitus Treatment Adjunct
Common side effects
- Decreases in blood pressure
- Nausea
- Dizziness
- Headache
- Vomiting
- Fatigue
- Syncope
- Diarrhea
- Cramps
Drug interactions
- alcohol
- dopamine antagonists, butyrophenones, phenothiazines, haloperidol, metoclopramide, pimozide
- strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors)
- macrolide antibiotics (e.g., erythromycin)
- octreotide
- other ergot alkaloids
Key clinical trials
- Dopamine Action on Metabolism in Relation to Genotype (PHASE2)
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets (PHASE3)
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (PHASE4)
- Bromocriptine for Patients With Schizophrenia and Prediabetes (PHASE4)
- Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (PHASE1,PHASE2)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa (EARLY_PHASE1)
- Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |